Leukemia, Eosinophilic, Acute

Phase 3 trials (11)

• tioguanine
• busulfan
• aldesleukin
• cyclosporine
• daunorubicin
• etoposide
• sargramostim
• cytarabine
• asparaginase
• autologous hematopoietic stem cells
• calcium phosphate

Phase 2 trials (25)

• azacitidine
• venetoclax
• lenalidomide
• cilengitide
• eltrombopag
• tacrolimus
• imatinib
• naltrexone
• beclomethasone
• idarubicin
• pevonedistat
• zarnestra
• allogeneic hematopoietic stem cells
• ruxolitinib
• mycophenolate
• cyclophosphamide
• bevacizumab
• beractant
• allogeneic lymphocytes
• triapine
• bortezomib
• ondansetron
• fludarabine
• mitoxantrone
• alvocidib

Phase 1 trials (9)

• sorafenib
• entinostat
• msk-2206
• xk469
• sunitinib
• tanespimycin
• tetanus-cmv fusion peptide vaccine
• vorinostat
• cefepime

Other trials (9)

• deferasirox
• foscarnet
• ganciclovir
• palifermin
• lithium
• Anti-thymocyte Globulin (Rabbit)
• valganciclovir
• melphalan
• interferon alpha-2b

Organization Involved with Phase 3 Indications (2)

• National Cancer Institute (NCI)
• Cancer and Leukemia Group B (CALGB)

Organization Involved with Phase 2 Indications (4)

• Case Western Reserve University
• Johns Hopkins University
• Southwest Oncology Group
• University of Texas at Houston

Organization Involved with Phase 1 Indications (7)

• GlaxoSmithKline
• Ohio State University
• University of Maryland
• University of South Florida
• University of Toronto
• Mayo Clinic
• State University of New York, Buffalo